ArticleFrontiers in pharmacology2019
Importance of Increasing Modifiable Risk Factors Knowledge on Alzheimer's Disease Among Community Pharmacists and General Practitioners in Spain.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Testing the knowledge of Alzheimer's diseaseFrontiers in public health · 2022Trial
- Involving Societal Stakeholders in Dementia Risk Reduction: An Explorative Study.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Implementing early detection of cognitive impairment in primary care to improve care for older adults.Journal of internal medicine · 2025Review
- Heterogeneity in the level of dementia literacy among community doctors in China: A latent profile analysis.Journal of global health · 2024Article
- Awareness of dementia risk factors among healthcare professionals at Hamad Medical Corporation, Qatar: a cross-sectional survey.Frontiers in public health · 2024Article
- Change in physical activity and systolic blood pressure trajectories throughout mid-life and the development of dementia in older age: the HUNT study.European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity · 2023Article
- Investigation on Awareness of Cognitive Impairment Diseases Among Surgical Practitioners.Neuropsychiatric disease and treatment · 2023Article
- Muscle strength performed better than muscle mass in identifying cognitive impairment risk in maintenance hemodialysis patients.Eating and weight disorders : EWD · 2022Article
- Lifestyle Variables Such as Daily Internet Use, as Promising Protective Factors against Cognitive Impairment in Patients with Subjective Memory Complaints. Preliminary Results.Journal of personalized medicine · 2021Article
- Pharmacists' Knowledge of Factors Associated with Dementia: The A-to-Z Dementia Knowledge List.International journal of environmental research and public health · 2021Article
- Quantifying Knowledge of Alzheimer's Disease: An Analysis of the Psychometric Properties of the Alzheimer's Disease Knowledge Scale.Neurology and therapy · 2021Article
- Spanish-dementia knowledge assessment scale (DKAS-S): psychometric properties and validation.BMC geriatrics · 2021Article
- Awareness of dementia risk reduction among current and future healthcare professionals: A survey study.Journal of public health research · 2021Article
- Pharmacist-Physician Interprofessional Collaboration to Promote Early Detection of Cognitive Impairment: Increasing Diagnosis Rate.Frontiers in pharmacology · 2021Article
- Assessing Knowledge and Perceptions of Alzheimer's Disease Among Employees of a Pharmaceutical Company in Spain: A Comparison Between Caregivers and Non-Caregivers.Patient preference and adherence · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community pharmacists and general practitioners have daily contact with patients with Alzheimer's disease (AD) but the number of positive cases constantly increases every day. Thus, the aim of this research is to describe the level of AD knowledge among community pharmacists and general practitioners in Spain, in order to see where the biggest gaps in the knowledge are. Therefore, a cross-sectional study has been carried out, using the Alzheimer's disease knowledge survey (ADKS), among members of the Spanish Society of Primary Care Physicians and the Spanish Society of Family and Community Pharmacy to report the differences in AD knowledge in both professional collectives. The ADKS has been responded by 578 community pharmacists and 104 general practitioners and consists of a battery of 30 questions, whose possible answers are true or false. It assesses the AD knowledge in seven areas (impact on the disease, risk factors, course of the disease, diagnosis, care, treatment and symptoms). Results indicate that Spanish pharmacists and general practitioners have a high personal knowledge of AD, nevertheless, it is not associated with greater awareness. Both scored above 80% at the categories: diagnostic, treatment and symptoms. However, lower knowledge level (60% of correct answers) was found in those related to risk factors, such as the ignorance about hypercholesterolemia or hypertension as risk factors for the disease. Community pharmacists are already acting to control cardiovascular risk factors, but a wider knowledge of the relationship of these factors to AD is needed to act against these silent risk factors. Thus, pharmacists may also be involved in the management of AD that includes recognizing early symptoms for early detection of cognitive impairment. Hence, knowledge about risk factors is very important in developing this expanding role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.